ChiRhoClin, Inc., a Maryland based family run corporation founded in 1991 by Dr. Edward D. Purich, is a research and development oriented pharmaceutical company focused on developing orphan drug products for the gastrointestinal and radiological community. Our emphasis is to develop orphan drug products that will diagnose and treat pancreatic gastrointestinal diseases and encourage research in the pancreatic area through our small pancreatic grant program.
ChiRhoClin's product is ChiRhoStim® (Human Secretin for Injection) an orphan drug that aids in the diagnoses of pancreatic cancer and pancreatic exocrine dysfunction.
ChiRhoStim® (Human Secretin for Injection) is approved for Pancreatic Function Testing, facilitating cannulation during ERCP, and Gastrinoma Testing. In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as MRCP, CT, and EUS.